111, Inc. Announces Fourth Quarter and Fiscal Year 2021 Financial Results
SHANGHAI, March 17, 2022 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021. Fourth Quarter 2021 Highlights Net revenues were RMB3.46 billion (US$543.1 million),...
MGI Helps Combat COVID-19 Pandemic in Laos with Innovative Container Laboratory Thanks to the Support of LSEA
PAKSE, Laos, March 17, 2022 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a global life science leader and innovator, has developed Champa LSEA Laboratory, the first 3rd party detection center in Laos, under the support of the Belt and Road Life Science Economy Alliance (LSEA) and Sithandone Joint Development Co., Ltd. (STD) to help Laos boost its mass Covid-19...
Hydro-Nanogel, an Innovative Bath-substituting Product for Clean, Cuddly, and Healthy Pets
BANGKOK, March 17, 2022 /PRNewswire/ -- Chula Veterinary Science (CUVET) releases its cutting-edge innovation, "Hydro-Nanogel", a bath-substituting cleansing product for pets. The Hydro-Nanogel is great for pet care when they are not allowed to bathe, or hate taking a bath, it is poised to be further developed for bedridden patients. Many...
Henlius 2021 Annual Results: New Record in Performance, Evolving to Biopharma
SHANGHAI, March 17, 2022 /PRNewswire/ -- Henlius (2696.HK) announced its annual results for the year ended December 31st, 2021, sharing the company's recent noteworthy progress and achievements. As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide with 4 products launched in China, 1 in Europe, and 12 indications around...
Breakthrough Study Validates Artificial Intelligence as a Novel Biomarker in Predicting Immunotherapy Response – Published in Journal of Clinical Oncology
Lunit's latest study provides evidence for Lunit SCOPE IO's ability to predict immunotherapy response This is the first study that adopted AI technology to define the tumor immune phenotype and to demonstrate its ability in predicting treatment outcomes of anti-PD-L1 therapy SEOUL, South Korea, March 16, 2022 /PRNewswire/ --...
SyMap Targets Renal Denervation With a Unique Map-and-Ablate Technology
SUZHOU, China, March 16, 2022 /PRNewswire/ -- SyMap Medical is developing a selective map-and-ablate technology that has the potential to substantially improve outcomes following renal denervation for treatment-resistant hypertension. Recent setbacks in renal denervation (RDN) clinical trials have delayed US market approval, and have once again raised questions about the ultimate clinical...
Terran Biosciences announces licensing deal with Columbia University for exclusive worldwide rights to proprietary CNS biomarker software platform
NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights...
Waterdrop Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results on March 23, 2022
BEIJING, March 16, 2022 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021, before U.S. markets open on Wednesday, March 23,...
Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab
SAN DIEGO and SUZHOU, China, March 16, 2022 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced FDA clearance to proceed with a Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with the anti-PD-1 antibody pembrolizumab. The global trial (ADG126-P001 / KEYNOTE-C98) will...
Innoforce and Hibiscus BioVentures Announce Strategic Partnership to Enable Development of Advanced Therapies
- Partnership enables Hibiscus BioTechnology Studio Companies access to Innoforce's advanced therapies drug development capabilities - HANGZHOU, China and ROCKVILLE, Md., March 16, 2022 /PRNewswire/ -- Innoforce, a global development and biomanufacturing company focused on Advanced Therapy Medicinal Products ("ATMPs"), and Hibiscus BioVentures, a firm committed to building patient-focused companies around transformative technologies, today...
